Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lodapolimab (Primary) ; LY 3321367 (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Bladder cancer; Bone cancer; Carcinoma; Cervical dysplasia; Cholangiocarcinoma; Chondrosarcoma; Chordoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Hypopharyngeal cancer; Liver cancer; Mesothelioma; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer; Vulvovaginal cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 16 Oct 2023 Status changed from active, no longer recruiting to completed.
    • 18 Nov 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
    • 02 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top